leisure time -WSS

leisure time

author：comprehensive 2025-10-02 00:28:10 - browse：15193

Adam's take main illustration — Molly Ferguson/STAT

Cytokinetics was founded 26 years ago but has not yet developed a drug successfully to approval. That makes Tuesday’s Food and Drug Administration decision on its treatment for heart failure a big deal — except nearly everyone, even investors who own Cytokinetics — hopes the agency rules against it.

Hoping the FDA rejects the Cytokinetics drug, called omecamtiv mecarbil, is a relatively uncommon, up-is-down, down-is-up situation, but it makes sense in this case because the business and science of the drug are not aligned.

Consider: Cytokinetics shares rose in December when an outside group of experts convened by the FDA to examine omecamtiv’s benefits and risks recommended against the medicine’s approval. On Tuesday, the FDA is most likely to heed that advice and turn down the company’s marketing application.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Eli Lilly CEO gives to Mike Pence presidential super PAC

hotspot

explore

WSS

Information blocking fines are now fair game in health care

How the messy conversation about Dolly changed bioethics

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Federal weight loss drug coverage is 30 years out of date

UCB departs biotech trade group BIO

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

entertainment

leisure time

explore

Moonlake's readout produced a cash windfall. Risks remain

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Wildfire smoke exposes gaps in outdoor worker protections

Ahead of JPM, here's who's profiting most in health care

Psychedelics group wrestles with new pharma identity

J&J to buy cancer drug developer Ambrx Biopharma

Peter Hotez and the public health issue of online harassment

Federal weight loss drug coverage is 30 years out of date

Hepatitis C has a cure — but many Americans still lack access to it

The struggle to figure out which patients 'deserve' Wegovy

focus

House panel takes first step toward fixing drug shortages

PBMs drew scrutiny in House hearing — and so did pharma

JPM: CVS says Medicare Advantage patients are impacting profits

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Midwives could help bridge maternal health disparities in the U.S.

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

knowledge

hotspot

explore

hotspot